Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases

Morgan K. Groover, Jillian M. Richmond

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, 01605, USA

Abstract
Chemokines play important roles in homeostasis and inflammatory processes. While their roles in leukocyte recruitment are well-appreciated, chemokines play additional roles in the body, including mediating or regulating angiogenesis, tumor metastasis and wound healing. In this opinion article, we focus on the role of CXCR3 and its ligands in fibrotic processes. We emphasize differences of the effects of each ligand, CXCL9, CXCL10 and CXCL11, on fibroblasts in different tissues of the body. We include discussions of differences in signaling pathways that may account for protective or pro-fibrotic effects of each ligand in different experimental models and ex vivo analysis of human tissues. Our goal is to highlight potential reasons why there are disparate findings in different models, and to suggest ways in which this chemokine axis could be manipulated for the treatment of fibrosis.

Keywords
CXCR3, CXCL9, CXCL10, CXCL11, fibrosis, fibroblast, pericyte, endothelial cell
Corresponding author: Jillian M. Richmond (jillian.richmond@umassmed.edu)

Author roles: Groover MK: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Richmond JM: Conceptualization, Funding Acquisition, Project Administration, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: JMR is an inventor on patent application #15/851,651, “Anti-human CXCR3 antibodies for the Treatment of Vitiligo” which covers targeting CXCR3 for the treatment of vitiligo; and on patent #62489191, “Diagnosis and Treatment of Vitiligo” which covers targeting IL-15 and Trm for the treatment of vitiligo. MKG declares no competing interests.

Grant information: JMR is supported by the National Institutes of Health [R56AR075761], a Career Development Award from the Dermatology Foundation, a Target Identification in Lupus Award from the Lupus Research Alliance and a Concept Award from the US Department of Defense Lupus Research Program [#LR190030]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Groover MK and Richmond JM. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Groover MK and Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases [version 1; peer review: 1 approved] F1000Research 2020, 9:1197 https://doi.org/10.12688/f1000research.26728.1

First published: 05 Oct 2020, 9:1197 https://doi.org/10.12688/f1000research.26728.1
Introduction: understanding CXCR3’s typical and atypical functions

Chemokine receptors are a subgroup of class A G-protein coupled receptors (GPCRs) that are relatively conserved across eukaryotes. They bind to chemokine ligands, a special class of 8–10kDa chemotactic cytokines, which are classified based on their amino acid structure (e.g. CC, CXC, or CX3C). With a few exceptions, most ligand-receptor relationships are promiscuous, meaning that a single chemokine receptor has multiple ligands and a single chemokine can bind to multiple receptors. As of now, there are 18 known chemokine receptors with Gαi-dependent chemotactic activity, and 5 atypical (non-chemotactic, recycling or scavenging) chemokine receptors in humans. Many chemokines are considered inflammatory, as they recruit leukocytes during inflammatory responses. However, there are also homeostatic chemokines that are important for immune cell maturation, tissue development, and angiogenesis. Homeostatic chemokines often exhibit tissue tropism, providing signals for recirculating immune cells, paracrine signals for cells that comprise tissues, and even tumor growth and metastasis.

CXCR3 is typically considered to be an inflammatory chemokine receptor because it is expressed by leukocytes that migrate towards interferon-induced ligands to sites of tissue inflammation. However, CXCR3 is also expressed on non-hematopoietic cells including endothelial cells, where it plays roles in promoting or inhibiting angiogenesis, and fibroblasts, in which it mediates wound healing responses.

There are several examples of diseases where inflammation precedes or is admixed with fibrosis, including infectious diseases (e.g. schistosomiasis, tuberculosis), cancers (e.g. pancreatic cancer, post-irradiation breast cancer) and autoimmune diseases (e.g. hepatitis, pulmonary fibrosis in scleroderma and skin fibrosis in morphea). Hallmarks of inflammatory fibrosis include infiltration of leukocytes; activation of endothelium; fibroblast activation, migration, proliferation and differentiation; production of collagen and other extracellular matrix proteins; and increased collagen bundle thickness and disorganization. Data from our lab and others have demonstrated that the CXCR3 chemokine axis can mediate protective or pro-fibrotic signals depending upon the context of the involved organs. In this opinion article, we will discuss potential reasons for disparate findings, and provide our opinions about how this system can be targeted therapeutically for the treatment of fibrosis.

CXCR3 signaling pathways in leukocytes

CXCR3 has four extracellular domains that bind its ligands (CXCL9, CXCL10, and CXCL11), and four intracellular domains that mediate the receptor’s different functions. The differential involvement of CXCR3 receptor domains in ligand binding and subsequent differences in downstream signaling contribute to the complex nature of this chemokine system, which has been mapped out in leukocytes using mutational constructs and competition binding assays. Like many other GPCRs, CXCR3-mediated chemotaxis is pertussis-toxin sensitive. However, CXCR3 activates several other pathways in addition to Gα subunits that we will review below.

CXCR3 binding and activation requires ligand interactions with at least one sulfated tyrosine in the N terminus and an interaction with amino acid residue R216 in the second extracellular loop. The proximal 16 amino acid residues of the N terminus are required for CXCL10 and CXCL11 binding and activation, but not CXCL9 activation. R216 in the second extracellular domain plays no role in CXCL10 or CXCL11 binding or ligand-mediated internalization, but this residue is necessary to activate chemotaxis by all three CXCR3 ligands. Both the DRY site, which encompasses the R216, and the CXCR3 carboxyl terminus are essential for CXCL9-, CXCL10-, and CXCL11-induced chemotaxis, calcium mobilization, and Erk phosphorylation (Figure 1A).

CXCR3 ligands selectively activate different receptor internalization pathways via β-arrestin and Gαi family members. Differences in signaling pathway activation by each ligand is called biased agonism. CXCL10-induced receptor internalization relies on the CXCR3 carboxyl terminus, dynamin and β-arrestin1. CXCL11 is the most potent inducer of CXCR3 internalization, and dominant negative dynamin and β-arrestin 1 are unable to impede internalization. The third intracytoplasmic loop is required for maximal CXCL11-induced internalization (Figure 1A).

In T cells, Gα2 is required for mediating CXCR3 ligand signaling, whereas Gαi3 limits activation of this signaling pathway. Western blotting of peripheral blood leukocytes stimulated with CXCR3 ligands demonstrated that CXCL11 and, to a lesser extent, CXCL9/10 induce dose- and time-dependent phosphorylation of p44/42 MAPK (ERK) and Akt that is prevented by pertussis toxin treatment (inhibition of Gα subunit binding). However, inhibition of MEK/ERK (U0126 or PD98059) does not prevent CXCL11-mediated chemotaxis, whereas PLC inhibition (U73122), PI3K (wortmannin) or, to a lesser extent, AKT inhibition (LY294002) does abrogate or reduce human T cell migration, respectively. Akt activation in human T cells was recently reported to be dependent upon β-arrestin2.

There is increasing evidence that chemokine receptors can mediate JAK/STAT signaling, which has typically been attributed to common gamma chain cytokine signaling. While JAK activation downstream of CXCR3 has not yet been studied, STAT activation in response to incubation with CXCL9/10/11 has been assessed in T cell cultures; addition of recombinant CXCL9/10 activates STAT1/STAT5 to promote Th1 and/or Th17 differentiation via Tbet/RORγT expression, whereas CXCL11 activates STAT3/STAT6 via GATA3 expression to augment regulatory function.

CXCR3 signaling pathways in vascular endothelial cells, smooth muscle cells, pericytes and fibroblasts

CXCR3 is also expressed by some non-hematopoietic cells, including endothelial cells, smooth muscle cells and fibroblast subsets. In endothelial cells, CXCR3 ligands mediate pro- or anti-angiogenic signals depending upon the model and tissue of origin. CXCL10 inhibits VEGF-induced dermal endothelial cell motility and tube formation in vitro via cAMP, PKA and MEK inhibition of m-calpain; this likely serves as a way to...
CXCR3 signaling pathways in different cell types. (A) Major CXCR3 signaling pathways in leukocytes. CXCL9, CXCL10 or CXCL11 bind to CXCR3 to mediate chemotaxis and T cell skewing. Different domains facilitate ligand binding, with the N terminus of CXCR3 facilitating binding of CXCL10 and CXCL11. R216 in the second extracellular loop (green star) is required for chemotactic responses for all 3 ligands. All three ligands can induce calcium flux, pERK, and pAKT, though CXCL9/10 require Gαi2 for pERK and β-arrestin2 for pAKt. CXCL11 can activate PLC and PI3K/AKT to mediate migration independent of Gαi. Internalization of CXCR3 induced by CXCL9/10 requires the C terminus, whereas CXCL11 requires the 3rd intracellular loop. CXCL9/10 can activate STAT1/5 to enforce Tbet/RORγT expression, whereas CXCL11 activates STAT3/6 to enforce GATA3 expression. (B) CXCR3-dependent and independent signaling pathways in endothelial cells. CXCL10 activates STAT3/6 to enforce GATA3 expression. CXCL10 also exerts effects on endothelial cells independently of CXCR3, but in a manner that requires GAG binding. (C) CXCR3 signaling in pericytes. Pericytes activate Src, Ras/ERK and PI3K/AKT pathways downstream of CXCR3, which mediate chemotactic responses. Kidney pericytes exhibit increased proliferation downstream of CXCL9/10, which is ERK-dependent (inhibited by PD98059). Interferons inhibit proliferation of pancreatic stellate cells via STAT1, though it is unclear whether this response is via CXCR3 ligands. (D) Fibroblast responses to CXCR3 ligands. Intestinal myofibroblasts exhibit calcium flux and phosphorylation of PKB, ERK, p90RSK induced by all three ligands. All three ligands induce actin polymerization in a Rho-associated coiled coil-forming protein kinase (ROCK)-dependent manner that is independent of PI3K and Gai. Signaling in skin dermal fibroblasts has not been fully mapped, though CXCR3 deficiency leads to hypertrophic and hypercellular scarring in mice via increased extracellular matrix proteins, including tenascin C, fibronectin, type I & III collagen, MMP9 and decorin. Color key: CXCL9 = red; CXCL10 = blue; CXCL11 = yellow; CXCL9/10 = purple; CXCL9/10/11 = green.

CXCL10 inhibits angiogenesis late in the wound healing process17. CXCL10 exhibits angiostatic properties in non-small cell lung cancer and idiopathic pulmonary fibrosis18,19. CXCL10 is also able to induce angiostatic effects by binding glycosaminoglycans (GAGs) independently of CXCR320. However, CXCL10 induces migration, but not proliferation, of rat cardiac microvascular endothelial cells via the p38/FAK pathway21 and rat and mouse liver endothelial cell progenitors through an unknown pathway22 (Figure 1B).

Pericytes are contractile cells on capillaries and post-capillary venules in tissues that play integral roles in tissue healing
and remodeling\textsuperscript{23}. Examples include hepatic stellate cells in the liver, glomerular mesangial cells in the kidney and pancreatic stellate cells. Pericytes express CXCR3, and activate the Src, Ras/ERK, and PI3K/Akt pathways downstream of CXCR3 ligand binding\textsuperscript{24}. Inhibitor studies indicate that Src and subsequent Ras/ERK activation are required for chemotaxis of hepatic pericytes, which is in direct contrast to observations in T cells. PI3K/Akt also plays an important role in hepatic pericyte migration as evidenced by abrogation of CXCL10 migration in the presence of wortmannin or LY294002. In addition to chemotaxis, kidney pericytes exhibit increased proliferation downstream of CXCL9/10, which is ERK-dependent (inhibited by PD98059). Unlike hepatic pericytes, kidney pericytes exhibit a second wave of ERK phosphorylation following incubation with CXCL10. CXCR3 signaling in pancreatic stellate cells has not been as extensively mapped, but they respond to PDGF by activating Src-JAK2-STAT3\textsuperscript{35}. Interferons (IFNs), which drive expression of CXCR3 ligands, inhibit proliferation of pancreatic stellate cells via STAT1\textsuperscript{36} (Figure 1C).

CXCR3 plays a homeostatic role in wound healing and re-epithelialization responses by fibroblasts\textsuperscript{37-39}. CXCR3 deficiency leads to hypertrophic and hypercellular scarring in mice that have experienced skin trauma\textsuperscript{40,41}. While CXCR3-mediated signaling in skin fibroblasts has not been well-characterized, the consequence of loss of signaling during wound healing includes increases in extracellular matrix proteins including tenasin C, fibronectin, type I and III collagen, MMP9 and decorin 180 days post-wounding compared to WT controls\textsuperscript{42}.

Studies of CXCR3 signaling downstream of CXCL9 and CXCL10 in intestinal myofibroblasts have shown modest differences in signaling, including CXCL9/10-induced calcium flux at 10min versus 8min for CXCL11, and prolonged phosphorylation of PKB, ERK, p90RSK induced by all 3 ligands as compared to shorter phosphorylation time in peripheral blood leukocytes (e.g. 2-20min versus 1-2min)\textsuperscript{43}. All three ligands induce actin polymerization in a Rho-associated coiled-coil-forming protein kinase (ROCK)-dependent manner that is independent of PI3K and Gai (Figure 1D). Further detailed signaling pathway analyses for CXCL9/10/11 signaling are warranted in non-hematopoietic cells from different organs.

**Post-translational modifications, proteolytic processing and potential alternate receptors for the CXCR3 chemokine axis**

Post-translational modifications of the CXCR3 chemokine axis modulates the function and signaling ability of the ligands and their receptor. CXCL10/11 have heparin binding sites that allow it to be presented on endothelium\textsuperscript{44}. CXCL10 presentation by the endothelium requires oligomerization\textsuperscript{41}. CXCL10/11 may be ctitrullinated by peptidylarginine deiminase, which inhibits their ability to induce chemotaxis and calcium flux and reduces their ability to bind heparin\textsuperscript{45}. CXCR3 itself requires tyrosine sulfation to bind to its ligands and mediate chemotaxis\textsuperscript{46}.

CXCL9/10/11 are cleaved/truncated by CD26, and CXCL11 is cleaved by CD13\textsuperscript{46,47}. The CD26 truncations of CXCR3 ligands retain angiotastic activity while losing CXCR3-mediated signaling\textsuperscript{48}. The C’ terminus of CXCL9 can inhibit neutrophil migration via competition with CXCL8-mediated binding to heparin, heparan sulfate, and cellular GAGs, which normally facilitate adhesion to vessels and subsequent transmigration\textsuperscript{49-50}. CD13 is expressed by endothelial and epithelial cells as well as fibroblasts in angiogenic tissue, but not normal tissue\textsuperscript{51}. Truncation of just the first two amino acids in CXCL11 by CD13 abrogates Akt and ERK phosphorylation and greatly reduces calcium flux to prevent migration of CXCR3-transfected CHO cells\textsuperscript{52}. Truncation of the first six amino acids still retains angiostatic activity as assessed by scratch assay of endothelial cell cultures.

There are two other isoforms of CXCR3: CXCR3-B which binds to CXCL4 and mediates angiostatic effects in cultured human endothelial cells\textsuperscript{53}; and CXCR3-alt which binds CXCL11\textsuperscript{43}. Of note, C57BL/6 (B6) mice do not express CXCR3-B\textsuperscript{20}. The roles of CXCR3-B and CXCR3-alt in fibrosis have not been studied. CXCR3 can also crosstalk with CXCR4 and CXCR7 via CXCL11 and CXCL12\textsuperscript{44}. CXCR4 mediates profibrotic effects in the liver, while CXCR7 mediates more homeostatic regenerative responses\textsuperscript{45}. CXCL9 can induce heterologous desensitization of CXCR4 to its ligand CXCL12\textsuperscript{46}. Notably, autoantibodies against CXCR3 and CXCR4 correlate with increased lung and skin disease severity in scleroderma patients, though it is unclear exactly how these impact signaling\textsuperscript{47,48}. CXCL11 binds to CXCR7, which is expressed on activated endothelial cells, tumor cell lines and fetal liver cells\textsuperscript{49}. CXCL11 ligation by CXCR7, which has an affinity of 2-5nM, does not induce calcium flux or migration; rather it promotes survival and adhesion. CXCR7 has been proposed to be a scavenger receptor for CXCL11\textsuperscript{50}. CXCR7 can attenuate TGFβ signaling in the lung, though the role of CXCL11 in this process has not been studied\textsuperscript{45,46}.

**Profibrotic roles of CXCR3 ligands**

CXCR3 and its ligands are reported to promote fibrosis in certain disease models and organs. An important caveat to bear in mind when assessing B6 mouse models is that CXCL11 is not expressed in this strain due to a null mutation. However, CXCL9 and CXCL10 knockout mice were generated using 129 oocytes and were backcrossed to B6. Therefore, WT B6 mice express CXCL9 and CXCL10, CXCL9/- mice express CXCL10 and CXCL11, and CXCL10/- mice express CXCL9 and CXCL11. This means that while CXCL11 cannot be directly assessed in B6 models, insights about its function can be gleaned by comparing CXCL9/-, CXCL10/- and WT B6 mice.

The nephrotoxic serum nephritis model of inflammatory kidney disease, which exhibits tubulointerstitial fibrosis, is dependent on CXCR3 and CXCL9, but not CXCL10, as determined by histopathology and loss of renal function\textsuperscript{53}. CXCR3/- and CXCL9/- mice had fewer intrarenal activated T cells and macrophages, as well as fewer IgG glomerular deposits and antigen-specific IgG in serum. These data suggest that CXCR3 and CXCL9 initiate nephritis through cell-mediated events, which ultimately promote tubulointerstitial...
fibrosis. CXCL10-/- animals developed kidney disease similar to WT controls, indicating that any potential anti-fibrotic role of CXCL11 in the kidney is potentially nullified by profibrotic effects of CXCL9. Similarly, any potential profibrotic role of CXCL11 in CXCL9-/- mice may be nullified by antifibrotic effects of CXCL10. However, a Balb/c mouse model of unilateral ureteral obstruction-induced renal tubulointerstitial fibrosis was exacerbated by JAK inhibition, and STAT3 played a protective role. Several factors may contribute to the disparate findings between these models, namely whether the process is immune-mediated or obstructive nephropathy, which other signals are being disrupted by JAK inhibition, and whether all three CXCR3 ligands are present to balance pro- versus anti-fibrotic signaling (Table 1).

Morphea, or localized scleroderma, is an inflammatory fibrosing disease of the dermis and underlying tissue. Several studies have identified CXCR3 ligands as positively correlating with disease severity and activity in patients. Systemic sclerosis, or scleroderma, also exhibits upregulation of CXCR3 ligands that correlates with disease severity. Preliminary studies from our laboratory support a pro-fibrotic role of CXCL9 in the skin: CXCL9-/- mice are protected from bleomycin-induced skin fibrosis, and in vitro treatment of mouse and human fibroblasts with CXCL9 induces transcription of collagen 1a1 (coll1a1); these data are available on a preprint server and are currently undergoing peer review.

CXCL10 has pro-fibrotic effects in the liver, where it prevents NK cells from inactivating hepatic stellate cells. CXCL10-/- mice and WT mice treated with anti-CXCL10 antibody are protected from carbon tetrachloride-induced liver fibrosis. Hepatic stellate cells upregulate CXCR3 in response to carbon tetrachloride, and CXCL10 induces their migration but not proliferation. CXCL10 also mediates T and B cell aggregates in lymphoid tissue, which are essentially absent in CXCL10-/- mice (Table 1).

**Antifibrotic roles of CXCR3 ligands**

While CXCL9 has pro-fibrotic effects in renal and skin tissue, CXCL9 has direct angiostatic and antifibrotic effects in experimental models of pancreas and liver fibrosis. In the trinitrobenzene sulfonic acid (TNBS) induced-pancreatitis rat model, administration of anti-CXCL9 antibody worsened fibrosis, whereas administration of recombinant CXCL9 improved fibrosis, as assessed by trichrome staining and hydroxyproline assay (Table 1). In vitro stimulation of pancreatic stellate cells with CXCL9 downregulated TGFβ1 and col1a1 production by confocal microscopy. Of note, antibody and recombinant CXCL9 were administered subcutaneously (s.c.) to rats in this model. We hypothesize that this route of administration may have pulled inflammatory infiltrates away from the gastrointestinal (GI) tract and towards the skin, considering there was 1.5ng/mL CXCL9 in serum and approximately 30μg was administered s.c. daily (assuming average weight of 300g/rat at a dose of 100 μg/kg body weight).

In the carbon tetrachloride-induced liver fibrosis model, CXCR3-/- mice exhibited augmented liver damage at 24h. Follow-up studies from the same laboratory used mice treated exogenously with CXCL9, which reduced the severity of liver fibrosis as assessed by Sirius red staining, hydroxyproline assay, and α-SMA expression (Table 1). In vivo CXCL9 treatment also inhibited angiogenesis as assessed by CD31 staining and ultrasound visualization of liver perfusion. However, CXCL9 treatment did not impact the number of Th1-polarized, IFN-γ-positive cells in the liver amongst treatment groups. Treatment of endothelial cells in vitro with CXCL9 was able to inhibit VEGF-mediated proliferation and migration via PLCγ, JNK and ERK. In vitro treatment of hepatic stellate cells reduced TGFβ and col1a1 by protein and RNA.

While CXCL10 has profibrotic effects in the liver, CXCL10 limits lung fibrosis in the murine model of bleomycin-induced pulmonary fibrosis (Table 1). CXCR3-/- and CXCL10-/- mice display exaggerated pulmonary fibrosis after bleomycin administration, and transgenic mice overexpressing CXCL10 are protected from bleomycin-induced mortality. Bleomycin did not alter the T cell cytokine milieu in CXCL10-/- mice, weakening the support for the idea that CXCL10 might limit fibrosis by skewing T cell polarization to the Th1 phenotype as demonstrated in hepatitis models. CXCL10 also did not decrease lung tissue-derived angiogenic activity and von Willebrand Factor expression after bleomycin delivery, despite that angiogenesis is considered a rate-limiting step in the development of pulmonary fibrosis. CXCR3 mRNA, but not protein, was detected in lung fibroblasts. Rather, direct interaction of the heparin-binding domain of CXCL10 and syndecan-4 on the lung interstitial compartment inhibits fibroblast recruitment, TGFβ signaling and subsequent fibrosis. Similar findings were reported in myocardium, which required CXCL10 fibroblast responses through proteoglycans, and urethral fibrosis, in which CXCL10 signaling interfered with profibrotic TGFβ signaling.

Similar to CXCL10, CXCL11 attenuates lung fibrosis in the bleomycin mouse model and inhibits angiogenesis in the corneal micropocket assay (Table 1). A double-blind, placebo controlled study of 330 idiopathic pulmonary patients treated with subcutaneous IFN-γ 1b treatment exhibited increased CXCL11 in bronchoalveolar lavage fluid and plasma, with concomitant decreased elastin. The pro- and anti-fibrotic roles of the CXCR3 ligands in different organs are summarized in Table 2.

**Potential therapeutic manipulations of CXCR3 for the treatment of fibrosis**

To select how to manipulate CXCR3 and/or its ligands for the treatment of fibrosis, it is our opinion that the suspected cell-of-origin in the fibrotic response and the level of angiogenesis during fibrogenesis need to be assessed. Based on the evidence discussed above, we hypothesize that fibrosing disorders primarily mediated by pericyte-type cells that require ERK signaling and exhibit more angiogenesis as a disease
<table>
<thead>
<tr>
<th>Organ</th>
<th>Disease</th>
<th>Experimental model</th>
<th>Species</th>
<th>Effect on fibroblasts/fibrosis?</th>
<th>Study outcomes</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>Myocardial infarction</td>
<td>Spontaneous; isoproterenol-induced</td>
<td>Human; Rat</td>
<td>no direct effect shown</td>
<td>Increased migration of inflammatory infiltrates specifically to valves and correlated with amount of cardiac fibrosis. Increased fibrosis following MI; cytokines released by myocardium induced expression of CXCL9 which promoted fibroblast proliferation &amp; migration.</td>
<td>Lin et al., 2019; Faé et al., 2013; Nogueira et al., 2012</td>
</tr>
<tr>
<td>Rheumatic fever</td>
<td>Spontaneous</td>
<td>Human</td>
<td>Human</td>
<td>no direct effect shown</td>
<td>Increased migration of inflammatory infiltrates to valves and correlated fibrosis. Increased migration of inflammatory infiltrates specifically to valves and correlated with amount of cardiac fibrosis.</td>
<td>Faé et al., 2013; Nogueira et al., 2012</td>
</tr>
<tr>
<td>Kidney</td>
<td>Chronic glomerulonephritis</td>
<td>Spontaneous; induced</td>
<td>Beagle dog</td>
<td>no direct effect shown</td>
<td>Increased migration of inflammatory infiltrates to the heart; polymorphism CXCL9 rs10336 CC was associated with protection from progression to severe CCC.</td>
<td>Nogueira et al., 2012; Menke et al., 2008</td>
</tr>
<tr>
<td>Liver</td>
<td>Hepatic fibrosis</td>
<td>carbon tetrachloride-induced</td>
<td>Mouse</td>
<td>Pro-fibrotic</td>
<td>Pro-fibrotic; initiates fibrosis through cell-mediated events. May or may not influence skewing of Th1-polarized, IFN-γ-positive cells in the liver.</td>
<td>Menke et al., 2008; Sahin et al., 2012; Wasmuth et al., 2009</td>
</tr>
<tr>
<td>Liver</td>
<td>Liver cirrhosis</td>
<td>Spontaneous; induced</td>
<td>Human</td>
<td>no direct effect shown</td>
<td>No direct effect shown. Anti-fibrotic: initiates nephritis through cell-mediated events.</td>
<td>Menke et al., 2008; Sahin et al., 2012; Wasmuth et al., 2009</td>
</tr>
<tr>
<td>Liver</td>
<td>Hepatitis C Virus-associated fibrosis</td>
<td>Spontaneous; induced</td>
<td>Human</td>
<td>no direct effect shown</td>
<td>Low levels correlated with better survival following transjugular intrahepatic portosystemic shunt. Alleles/polymorphisms of CXCL9/10/11 are associated with protection of promotion of fibrosis. Alleles/polymorphisms of CXCL9/10/11 are associated with protection or promotion of fibrosis.</td>
<td>Berres et al., 2015; Jimenez-Sossa et al., 2017; Friesel-Tordera et al., 2015</td>
</tr>
<tr>
<td>Liver</td>
<td>Chronic pancreatitis</td>
<td>Spontaneous; induced</td>
<td>Rat</td>
<td>Anti-fibrotic</td>
<td>Attenuates fibrogenesis in vivo; has anti-fibrotic effects in vitro.</td>
<td>Silen et al., 2013; O'Brien et al., 2017; Mertens et al., 2018; Rabquer et al., 2011</td>
</tr>
<tr>
<td>Skin</td>
<td>Morphea</td>
<td>Spontaneous; induced</td>
<td>Human</td>
<td>no direct effect shown</td>
<td>Increased levels are documented in disease activity. Serum levels are correlated with disease activity.</td>
<td>O'Brien et al., 2017; Mertens et al., 2018; Rabquer et al., 2011</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Chronic pancreatitis</td>
<td>Spontaneous; induced</td>
<td>Human</td>
<td>Pro-fibrotic</td>
<td>Serum levels are correlated with disease activity. Serum levels are correlated with disease activity.</td>
<td>O'Brien et al., 2017; Mertens et al., 2018; Rabquer et al., 2011</td>
</tr>
<tr>
<td>Skin</td>
<td>Systemic sclerosis</td>
<td>Spontaneous; induced</td>
<td>Human</td>
<td>no direct effect shown</td>
<td>Increased levels are documented in disease activity. Serum levels are correlated with disease activity.</td>
<td>O'Brien et al., 2017; Mertens et al., 2018; Rabquer et al., 2011</td>
</tr>
</tbody>
</table>

**Table 1. Summary of the effects of each CXCR3 ligand in different organ systems and models of fibrosis.**
<table>
<thead>
<tr>
<th>Organ</th>
<th>Effect on fibroblasts/fibrosis?</th>
<th>Study outcomes</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCL10</td>
<td>Human</td>
<td>Increased migration of inflammatory cells to heart, CXCL10 expression in heart was associated with protection from progression to severe CCC</td>
<td>Nogueira et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Beagle dog</td>
<td>Not fully understood but seems to be dispensable for pathology</td>
<td>Menke et al., 2010</td>
</tr>
<tr>
<td>CXCL10</td>
<td>Mouse</td>
<td>Limits fibroblast migration to lung tissue</td>
<td>Tager et al., 2004, Jang, 2010</td>
</tr>
<tr>
<td>CXCL10</td>
<td>Human</td>
<td>Serum levels are correlated with disease activity</td>
<td>Mettens et al., 2018</td>
</tr>
<tr>
<td>CXCL10</td>
<td>Mouse</td>
<td>A direct effect on pulmonary fibroblasts was not observed</td>
<td>Hasegawa et al., 2011, Liu et al., 2013, Rabquer et al., 2011</td>
</tr>
<tr>
<td>CXCL11</td>
<td>Mouse</td>
<td>Reduced pulmonary collagen deposition, procollagen gene expression, and histopathologic fibroplasia and extracellular matrix deposition in the lung. CXCR3 is not expressed on pulmonary fibroblasts.</td>
<td>Burdick et al., 2005, Suppe et al., 2004</td>
</tr>
<tr>
<td>CXCL4 (binds CXCR3-B)</td>
<td>Mouse</td>
<td>Directly interrupts VEGF signaling, no direct effect on pulmonary fibroblasts.</td>
<td>Sulpice et al., 2004</td>
</tr>
</tbody>
</table>

**Table 1 Complete References:**

Table 2. Comparison of CXCR3 ligand actions in organ fibrosis.

<table>
<thead>
<tr>
<th></th>
<th>CXCL9</th>
<th>CXCL10</th>
<th>CXCL11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profibrotic</strong></td>
<td>Heart, Kidney, Skin</td>
<td>Heart, Liver</td>
<td>?</td>
</tr>
<tr>
<td><strong>Antifibrotic</strong></td>
<td>Liver, Pancreas</td>
<td>Lung</td>
<td>Lung</td>
</tr>
</tbody>
</table>

feature would be more dependent upon CXCL10, and fibrosing disorders primarily mediated by fibroblast or myofibroblast-type cells that require AKT and JAK signaling and exhibit less vascular involvement would be more dependent upon CXCL9. For example, hepatic fibrosis has prominent vascular changes and is driven by hepatic stellate cells and CXCL10, whereas morphea has a low incidence of vascular changes and is driven by fibroblasts/myofibroblasts and CXCL9. GI organs, in which fibrosis is driven by pericytes, also generally seem to use CXCL9 for protective responses, whereas lung and skin, in which fibrosis is driven by fibroblast subsets, use CXCL10 for protective responses. Nuances in the signaling pathways, the relative chemokine responsiveness, as well as potential coreceptors, will need to be addressed in future studies. Technologies such as single cell RNA sequencing and proteomics may ultimately help resolve the heterogeneity of chemokine receptor and coreceptor expression, as well as preferential signaling pathway usage.

The first potential class of small molecules that could be used to disrupt CXCR3-mediated inflammatory fibrosis are JAK inhibitors. We and others have shown that JAK inhibitors prevent fibrosis in mice\(^\text{67,68}\), and demonstrated efficacy in our case studies of human morphea patients who were recalcitrant to standard therapies\(^\text{69,70}\). In our study of intradermal bleomycin injection in mice and human morphea tissue, we observed p-STAT1 and p-STAT3 activation in both immune infiltrates and cells with fibroblast morphology\(^\text{71}\). Notably, STAT1, STAT3 and STAT5 have predicted binding sites in the collagen 1a1 (coll1a1) promoter and enhancer regions (GeneCards), which may account for our observation that JAK inhibitors were able to suppress coll1a1 transcription by human and mouse fibroblasts in vitro\(^\text{72}\). We also noted that the JAK 1/2 inhibitor ruxolitinib yielded a slightly better p value than the JAK 3>>1>2 inhibitor tofacitinib for inhibition of dermal thickening in the intradermal bleomycin mouse model. These data are in agreement with previously published studies examining JAK2 as a driver of fibrosis in scleroderma fibroblasts and a bleomycin mouse model\(^\text{73}\). Zhang et al demonstrated that following long-term selective inhibition of JAK2, JAK2 may be transphosphorylated by JAK1 to mediate fibrosis\(^\text{74}\), supporting the use of a combination JAK1/2 inhibitor for treatment of fibrosis. It is interesting to note that ruxolitinib was originally FDA approved for myelofibrosis\(^\text{75}\), and patients receiving ruxolitinib therapy often resolve fibrosis\(^\text{76}\). While this is encouraging for potential repurposing of ruxolitinib for other fibrosing diseases, we would caution that careful tapering and monitoring is needed to prevent potential rebound effects\(^\text{77,78}\). Cessation of ruxolitinib can cause hyperphosphorylation of JAK2, increasing inflammation and subsequent fibrosis\(^\text{79}\). Selecting a JAK1/2 inhibitor with a longer half-life, such as baricitinib\(^\text{80}\), might be a safer option for patients who are tapering.

The second potential class of therapeutics would be agonist peptides to mimic the antifibrotic role of CXCL10 for lung fibrosis. As suggested by Tager and Jiang et al, maintaining heparin binding but excluding CXCR3 binding would mitigate potential toxicities related to T cell recruitment\(^\text{81,82}\). CXCL10-based therapeutics might also prove useful for improving lung fibrosis and function in patients recovering from infectious lung disease, particularly Sars-CoV2 infection/COVID-19 disease\(^\text{83}\). Smith et al recently reported biased agonists of CXCR3 that can differentially mediate inflammation and migration of immune cells which they examined in the context of contact hypersensitivity in skin\(^\text{84}\), providing a basis for the feasibility of this approach.

The third potential class of therapeutics would be agents that inhibit the pro-fibrotic signaling events mediated by CXCR3 ligands, such as CXCL9 in Th1IFNγ-driven kidney disease or morphea. These approaches could include anti-CXCL9 blocking/neutralizing antibodies, CXCL9 siRNA, or antagonistic peptide ligands. Of note, antibody neutralization of CXCL10 for treatment of hepatic fibrosis may be challenging, as CXCL10 antibodies neutralize the free form and not endothelial-bound chemokine\(^\text{85}\). Similar challenges may arise when attempting to neutralize CXCL9 with antibody, as would anti-drug antibody responses.

A fourth class of therapeutics could leverage the cell- or organ-specific context of chemokine expression. For example, stimulating γδ T-cells to produce CXCL10 in the lung could have therapeutic benefits in pulmonary fibrotic disease. Inhibiting macrophage production of CXCL9 in the skin could prevent collagen deposition in morphea. Drawing immune infiltrates away from the pancreas and towards the skin could reset the fibrotic process, as in the TNBS-induced rat model. Agents are in development to target specific cell types, such as antibody-drug conjugates\(^\text{86}\), some with cleavable linkers\(^\text{87}\), bispecific antibodies\(^\text{88,89}\) and nanoparticles\(^\text{90}\), which can be preferentially phagocytosed by antigen presenting cells of the immune system. These could be leveraged to achieve the aforementioned goals of stimulating CXCL10 or inhibiting CXCL9 production by key cell types. Different drug delivery routes and systems may also help accomplish the goal of drawing immune cells away from the pancreas or other organs, with cutaneous administration via creams, injections or microneedle patches\(^\text{91}\) helping to achieve a high local concentration.

A fifth class of therapeutics could leverage existing enzymatic cleavage of CXCR3 ligands. Reombinant peptides lacking amino-terminal amino acids can exert angiostatic effects, while inhibiting CXCR3-mediated migration. Administration of bioactive CD26 and/or CD13, or inhibitors of these enzymes, may modulate fibrotic processes in specific organs or diseases. CD26 inhibitors have been reported to reduce or prevent fibrosis in models of myocardial fibrosis, lung fibrosis and kidney fibrosis\(^\text{92-94}\), and a CD13 inhibitor improved fibrosis in a mouse model of silica-induced lung fibrosis\(^\text{95}\).
Last, combination therapies targeting both prevention of inflammation and fibrosis in addition to promoting tissue remodeling will likely provide the best therapeutic outcome for fibrosis patients. Tissue remodeling will ultimately allow for breakdown of fibrotic plaques and better disease outcomes, which could be achieved through agonists or inducers of matrix metalloproteinases (MMPs) or antagonists of tissue inhibitors of MMPs (TIMPs).

Conclusion

The differential impact of CXCR3 and its ligands on tissues depends on disparate signaling pathways involving multiple cell types and potential coreceptors; the nuances of which should be addressed in future research involving single cell RNA sequencing and proteomics. As we have examined the known fibrotic and antifibrotic roles of CXCR3 and its ligands, we suggest that future therapeutic options should be centered around the suspected cell-of-origin in the fibrotic response, tissue-specific signaling factors and the degree of angiogenesis is during fibrosis. Likely, a combination of these therapies will have the best potential to ameliorate symptoms of patients with fibrosing diseases.

Data availability

No data are associated with this article.

Acknowledgements

We thank M. Tuzova and C. Garelli for insightful comments.

References


Open Peer Review

Current Peer Review Status: ✔️

Version 1

Reviewer Report 16 October 2020

https://doi.org/10.5256/f1000research.29512.r72473

© 2020 Sadik C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔️ Christian D. Sadik

1 Department of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany
2 Center for Research on Inflammation of the Skin (CRIS), Lübeck, Germany

The review focuses on the role of CXCR3 and its ligands in fibrotic processes. It starts with an excellent overview on the complex receptor pharmacology of CXCR3 and continues to exhaustively summarize and discuss the role of CXCR3 in the fibrotic processes in different organs.

The review is very illustrative including excellent figures. The current state of knowledge on CXCR3 and its role in fibrotic processes is comprehensively summarized and discussed in a balanced manner. All in the article are supported by the literature, which is adequately cited.

Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes

Are all factual statements correct and adequately supported by citations?
Yes

Are arguments sufficiently supported by evidence from the published literature?
Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: My areas of research are innate immunity, immomediators, immunopharmacology, and autoimmune and autoinflammatory diseases

I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com